Market research
EVLO Evelo Biosciences Inc
PINK USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2K
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- -25.24
Profile
Company facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US2997341035
- Market cap
- 2K
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- Not available
- Beta
- -25.24
About
About Evelo Biosciences Inc
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EVLO discussion.
5 years, 4 months ago
Evelo Biosciences, Inc is currently in a long term uptrend where the price is trading 17.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Evelo Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 28.5% to $-29M since the same quarter in the previous year.
Finally, its free cash flow grew by 0.5% to $-19M since the same quarter in the previous year.
Based on the above factors, Evelo Biosciences, Inc gets an overall score of 3/5.